Top Markets
Coin of the day
CSL Limited CSL Limited

CSL Limited

CSL
株式のランク #432
CSL Limited researches, develops, manufactures, markets, and distributes... CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and allied products in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through two segments, CSL Behring and CSL Seqirus. The CSL Behring segment offers plasma therapies, such as plasma products and recombinants. This segment also conducts research on plasma and non-plasma therapies; and receives license and royalty from the commercialization of intellectual property. The CSL Seqirus segment manufactures and distributes non-plasma biotherapeutic products; and develops influenza related products. CSL Limited was founded in 1916 and is headquartered in Parkville, Australia.
株価
$99.32
時価総額
$48.20B
変化(1日)
0.98%
変化(1年)
-32.14%
AU
取引 CSL Limited (CSL)

カテゴリー

CSL Limited(CSL)の収益
Dec 2025 時点の収益 TTM: $15.70B
CSL Limited の最新の財務報告によると、現在の収益 (TTM) は $15.70B です。2024 年には $14.69B の収益があり、これは 2023 年の $13.17B と比較して 増加 です。収益とは、企業が商品やサービスの販売によって得る総所得です。利益とは異なり、費用は差し引かれません。
CSL Limited の収益履歴(2000 ~ 2026)
各年末の収益
収益 変化
2026 (TTM) $15.70B 1.72%
2025 $15.43B 5.04%
2024 $14.69B 11.51%
2023 $13.17B 25.55%
2022 $10.49B 1.56%
2021 $10.33B 9.84%
2020 $9.41B 13.08%
2019 $8.32B 11.54%
2018 $7.46B 6.28%
2017 $7.02B 15.81%
2016 $6.06B 11.00%
2015 $5.46B 8.91%
2014 $5.01B 10.79%
2013 $4.52B -2.44%
2012 $4.64B -3.37%
2011 $4.80B 49.63%
2010 $3.21B 6.25%
2009 $3.02B -7.53%
2008 $3.26B 42.87%
2007 $2.28B 45.52%
2006 $1.57B -1.58%
2005 $1.60B 98.59%
2004 $803.28M 36.45%
2003 $588.71M 38.88%
2002 $423.90M -2.21%
2001 $433.49M 0.00%
2000 0.00 0.00%
同業他社の収益
企業 収益 収益の差
$48.55B 209.32%
DK
$12.04B -23.30%
US
$14.34B -8.62%
US
$9.08B -42.13%
BE
$5.49B -65.01%
NL